Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea · Delayed Price · Currency is KRW 8,430.00
-50.00 (-0.59%)
At close: Apr 16, 2026
Kwang Dong Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 20,968 | 40,481 | 36,966 | 24,174 | 24,019 |
Depreciation & Amortization | 18,055 | 14,532 | 12,904 | 14,017 | 14,110 |
Loss (Gain) From Sale of Assets | -7,677 | -3,026 | 1,964 | -166.52 | -38.87 |
Asset Writedown & Restructuring Costs | 2,590 | - | - | - | - |
Loss (Gain) From Sale of Investments | -7,050 | -25,399 | -9,412 | 1,932 | 10,232 |
Loss (Gain) on Equity Investments | 11,441 | -767.76 | 429.82 | 435.51 | 112.22 |
Stock-Based Compensation | 238.29 | - | - | - | 17.59 |
Provision & Write-off of Bad Debts | 0.58 | 2,421 | 517.29 | 478.81 | -497.04 |
Other Operating Activities | 13,828 | 10,174 | 14,103 | 15,731 | 10,883 |
Change in Accounts Receivable | 1,966 | -12,401 | -22,482 | 15,134 | -14,988 |
Change in Inventory | 15,419 | -33,422 | -33,194 | -16,568 | 15,153 |
Change in Accounts Payable | 21,772 | -1,309 | -7,213 | 20,501 | -2,987 |
Change in Unearned Revenue | -97.6 | 19.34 | -40.2 | 0.4 | 58.4 |
Change in Other Net Operating Assets | -9,011 | -4,141 | -6,273 | -12,848 | -1,134 |
Operating Cash Flow | 82,341 | -12,153 | -11,730 | 62,822 | 54,940 |
Operating Cash Flow Growth | - | - | - | 14.35% | 140.66% |
Capital Expenditures | -29,862 | -75,730 | -34,785 | -25,383 | -23,795 |
Sale of Property, Plant & Equipment | 992.73 | 5,483 | 4,050 | 306.46 | 263.45 |
Cash Acquisitions | -13,597 | - | - | - | - |
Sale (Purchase) of Intangibles | -1,085 | -1,937 | -331.65 | -616.83 | -651.85 |
Investment in Securities | -74,370 | 86,121 | -14,583 | -17,896 | -18,993 |
Other Investing Activities | 11,472 | -2,395 | -26,295 | 200.59 | 443.5 |
Investing Cash Flow | -102,578 | 12,772 | -71,831 | -42,747 | -42,976 |
Short-Term Debt Issued | 105,400 | 568,500 | 264,000 | 119,000 | 116,000 |
Long-Term Debt Issued | - | 49,888 | 10,000 | - | 22,000 |
Total Debt Issued | 105,400 | 618,388 | 274,000 | 119,000 | 138,000 |
Short-Term Debt Repaid | -108,934 | -549,605 | -205,000 | -99,000 | -106,000 |
Long-Term Debt Repaid | -8,303 | -25,093 | -1,657 | -16,510 | -11,913 |
Total Debt Repaid | -117,237 | -574,698 | -206,657 | -115,510 | -117,913 |
Net Debt Issued (Repaid) | -11,837 | 43,690 | 67,343 | 3,490 | 20,087 |
Issuance of Common Stock | 61,652 | - | - | - | - |
Repurchase of Common Stock | -364.46 | -4,067 | -6,235 | - | - |
Dividends Paid | -3,928 | -4,008 | -4,108 | -4,108 | -4,108 |
Other Financing Activities | -6.47 | 1,150 | 1,010 | -10.5 | -85.54 |
Financing Cash Flow | 45,517 | 36,765 | 58,010 | -628.26 | 15,894 |
Foreign Exchange Rate Adjustments | -477.37 | 1,461 | -657 | 139.36 | 1,226 |
Miscellaneous Cash Flow Adjustments | -0 | 0 | 0 | -0 | 0 |
Net Cash Flow | 24,802 | 38,845 | -26,208 | 19,587 | 29,084 |
Free Cash Flow | 52,479 | -87,883 | -46,515 | 37,439 | 31,145 |
Free Cash Flow Growth | - | - | - | 20.21% | 77.30% |
Free Cash Flow Margin | 3.16% | -5.36% | -3.07% | 2.61% | 2.33% |
Free Cash Flow Per Share | 1303.94 | -2194.85 | -1149.35 | 911.36 | 757.27 |
Cash Interest Paid | 10,569 | 11,651 | 7,506 | 3,748 | 2,369 |
Cash Income Tax Paid | 8,781 | 13,598 | 10,366 | 13,692 | 11,370 |
Levered Free Cash Flow | 101,739 | -139,015 | -58,701 | 35,407 | 59,535 |
Unlevered Free Cash Flow | 108,617 | -132,594 | -54,386 | 37,741 | 61,125 |
Change in Working Capital | 30,049 | -51,254 | -69,201 | 6,220 | -3,898 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.